PIQ
vs
S
S&P/ASX 300
PIQ
Over the past 12 months, PIQ has underperformed S&P/ASX 300, delivering a return of -49% compared to S&P/ASX 300's +1% growth.
Stocks Performance
PIQ vs S&P/ASX 300
Performance Gap
PIQ vs S&P/ASX 300
Performance By Year
PIQ vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Proteomics International Laboratories Ltd
Glance View
Proteomics International Laboratories Ltd is a medical technology and life sciences company built around protein biomarker science. It discovers and validates disease markers in blood and other samples, then turns that research into laboratory tests and diagnostic products. It also offers specialist proteomics research services to drug developers, universities, and other life science groups that need help identifying or measuring proteins. The company makes money in a few ways: by selling diagnostic tests and test kits, by charging for research and analytical services, and by licensing or commercializing its biomarker intellectual property. Its customers include hospitals, doctors, laboratories, researchers, and pharmaceutical companies that need better tools for early detection, disease monitoring, or drug development. What sets the business apart is that it sits between scientific discovery and routine healthcare use. Proteomics International does not just run a lab; it tries to turn protein research into practical tests that can be used in clinical settings. That gives it a role as both a specialist service provider and a developer of diagnostics based on its own biomarker pipeline.
